A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Nanobiotechnology

Topics

Chemistry

Biochemistry

Medicine

Immunology

Internal Medicine

Show all topics

DOI

10.1186/s12951-024-02525-1

License

CC-BY

Other Formats

PDF